BioXcel Therapeutics (BTAI) Total Liabilities (2017 - 2026)

BioXcel Therapeutics' Total Liabilities history runs 10 years deep, the most recent figure standing at $139.6 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 8.41% year-over-year to $139.6 million in Q1 2026; TTM through Mar 2026 was $139.6 million, a 8.41% increase from a year earlier, with the FY2025 full-year figure at $140.4 million, up 6.8% from the prior year.
• Total Liabilities fell to $139.6 million in Q1 2026 per BTAI's latest filing, from $140.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $154.7 million in Q1 2024 and bottomed at $17.0 million in Q1 2022.
• The 5-year median for Total Liabilities is $133.5 million (2025), against an average of $124.5 million.
• Across the five-year window, Total Liabilities surged 646.91% in 2022 and slipped 16.77% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $129.1 million in 2022, then gained by 0.88% to $130.2 million in 2023, then advanced by 0.94% to $131.4 million in 2024, then gained by 6.8% to $140.4 million in 2025, then declined by 0.58% to $139.6 million in 2026.
• Per Business Quant, the three latest BTAI Total Liabilities figures stand at $139.6 million (Q1 2026), $140.4 million (Q4 2025), and $133.7 million (Q3 2025).